Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and central nervous disorders:

Neurological Aspects of Medical Use of Cannabidiol. Mannucci C et al. CNS Neurol Disord Drug Targets. (2017)

Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. Kozela E et al. Int J Mol Sci. (2017)

Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Zlebnik NE et al. Annu Rev Neurosci. (2016)

Search results

Items: 1 to 20 of 76

1.

Cannabidiol in Anxiety and Sleep: A Large Case Series.

Shannon S, Lewis N, Lee H, Hughes S.

Perm J. 2019;23. pii: 18-041. doi: 10.7812/TPP/18-041.

2.

Computational systems pharmacology analysis of cannabidiol: a combination of chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation.

Bian YM, He XB, Jing YK, Wang LR, Wang JM, Xie XQ.

Acta Pharmacol Sin. 2019 Mar;40(3):374-386. doi: 10.1038/s41401-018-0071-1. Epub 2018 Sep 10.

PMID:
30202014
3.

Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels.

Sales AJ, Crestani CC, Guimarães FS, Joca SRL.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:255-261. doi: 10.1016/j.pnpbp.2018.06.002. Epub 2018 Jun 6.

PMID:
29885468
4.

Novel treatment options in depression and psychosis.

Ceskova E, Silhan P.

Neuropsychiatr Dis Treat. 2018 Mar 13;14:741-747. doi: 10.2147/NDT.S157475. eCollection 2018. Review.

5.

Cannabis-based medicines for chronic neuropathic pain in adults.

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W.

Cochrane Database Syst Rev. 2018 Mar 7;3:CD012182. doi: 10.1002/14651858.CD012182.pub2. Review.

PMID:
29513392
6.

Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review.

Farzaei MH, Shahpiri Z, Bahramsoltani R, Nia MM, Najafi F, Rahimi R.

CNS Drugs. 2017 Oct;31(10):867-889. doi: 10.1007/s40263-017-0466-4. Review.

PMID:
28948486
7.
8.

Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats.

Karimi-Haghighi S, Haghparast A.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:307-313. doi: 10.1016/j.pnpbp.2017.08.022. Epub 2017 Sep 1.

PMID:
28870635
9.

Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis.

González-García C, Torres IM, García-Hernández R, Campos-Ruíz L, Esparragoza LR, Coronado MJ, Grande AG, García-Merino A, Sánchez López AJ.

Exp Neurol. 2017 Dec;298(Pt A):57-67. doi: 10.1016/j.expneurol.2017.08.017. Epub 2017 Sep 1.

PMID:
28867485
10.

Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid.

Kozela E, Juknat A, Vogel Z.

Int J Mol Sci. 2017 Jul 31;18(8). pii: E1669. doi: 10.3390/ijms18081669. Review.

11.

Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.

Santoro M, Mirabella M, De Fino C, Bianco A, Lucchini M, Losavio F, Sabino A, Nociti V.

J Neurol Sci. 2017 Aug 15;379:298-303. doi: 10.1016/j.jns.2017.06.017. Epub 2017 Jun 15.

PMID:
28716266
12.

Sleep disturbances and severe stress as glial activators: key targets for treating central sensitization in chronic pain patients?

Nijs J, Loggia ML, Polli A, Moens M, Huysmans E, Goudman L, Meeus M, Vanderweeën L, Ickmans K, Clauw D.

Expert Opin Ther Targets. 2017 Aug;21(8):817-826. doi: 10.1080/14728222.2017.1353603. Epub 2017 Jul 12. Review.

PMID:
28685641
13.

Neurological Aspects of Medical Use of Cannabidiol.

Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G.

CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi: 10.2174/1871527316666170413114210. Review.

PMID:
28412918
14.

Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Rosenberg EC, Patra PH, Whalley BJ.

Epilepsy Behav. 2017 May;70(Pt B):319-327. doi: 10.1016/j.yebeh.2016.11.006. Epub 2017 Feb 9. Review.

15.

Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.

Allendorfer JB, Szaflarski JP.

Epilepsy Behav. 2017 May;70(Pt B):349-354. doi: 10.1016/j.yebeh.2016.11.020. Epub 2017 Jan 18. Review.

PMID:
28109780
16.

Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells.

Libro R, Diomede F, Scionti D, Piattelli A, Grassi G, Pollastro F, Bramanti P, Mazzon E, Trubiani O.

Int J Mol Sci. 2016 Dec 23;18(1). pii: E26. doi: 10.3390/ijms18010026.

17.

Evolution of multiple sclerosis spasticity-associated symptoms: latest data.

Flachenecker P.

Neurodegener Dis Manag. 2016 Dec;6(6s):9-12. Review.

PMID:
27874495
18.

Medical Marijuana: Just the Beginning of a Long, Strange Trip?

Ciccone CD.

Phys Ther. 2017 Feb 1;97(2):239-248. doi: 10.2522/ptj.20160367. Review.

PMID:
27660328
19.

Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.

Squintani G, Donato F, Turri M, Deotto L, Teatini F, Moretto G, Erro R.

J Neurol Sci. 2016 Nov 15;370:263-268. doi: 10.1016/j.jns.2016.09.054. Epub 2016 Sep 28.

PMID:
27772772
20.

Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®.

Carotenuto A, Iodice R, Petracca M, Inglese M, Cerillo I, Cocozza S, Saiote C, Brunetti A, Tedeschi E, Manganelli F, Orefice G.

Acta Neurol Scand. 2017 Apr;135(4):442-448. doi: 10.1111/ane.12660. Epub 2016 Aug 8.

PMID:
27500463

Supplemental Content

Loading ...
Support Center